{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:03:12Z","timestamp":1776484992824,"version":"3.51.2"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Global Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Legal-involved veterans with opioid use disorder (OUD) have lower receipt of medications for opioid use disorder (MOUD) than other veterans served at the Veterans Health Administration (VHA). This qualitative study examined the influence of the criminal justice system on access to MOUD for legal-involved veterans in the U.S.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>VHA facilities (<jats:italic>n<\/jats:italic>\u2009=\u200914) that varied in their provision of MOUD to legal-involved veterans were selected for qualitative interviews. Interviewees included legal-involved veterans (<jats:italic>n<\/jats:italic>\u2009=\u200918), VHA Veterans Justice Programs Specialists (<jats:italic>n<\/jats:italic>\u2009=\u200915), substance use disorder treatment providers (<jats:italic>n<\/jats:italic>\u2009=\u20095), and criminal justice staff (<jats:italic>n<\/jats:italic>\u2009=\u200912). Team members applied codes to meaningful units of analysis (quotations) in the transcribed interviews. Using a matrix approach, team members created a spreadsheet matrix with codes, facility rate of MOUD, and relevant quotations summarized for each participant. Themes and connections between individual participants and cross-interview concepts were explored. Participants were not asked to provide feedback on the findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Themes identified were as follows: (1) Veterans Treatment Court policies both enhanced and limited MOUD treatment access and utilization among participants; (2) cross-system collaboration strengths and challenges existed; and (3) criminal justice system treatment preferences and policies both enhanced and limited MOUD in jails and prisons.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The influence of the criminal justice system on MOUD has led to variable access to MOUD for legal-involved veterans. Our findings can help inform recommendations to enhance access to MOUD for veterans within the criminal justice system, including the development of a national database of MOUD education materials for Veterans Treatment Courts, strengthening community-court relationships, allowing individuals to use their own healthcare coverage within jails and prisons and extend Medicaid coverage into criminal justice settings, and applying national quality measures for MOUD to criminal justice settings and develop a national system for tracking these quality measures.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s44263-024-00093-y","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T23:01:37Z","timestamp":1726700497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Influences of the criminal justice system on use of medications for opioid use disorder: a qualitative study"],"prefix":"10.1186","volume":"2","author":[{"given":"Emmeline","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Stimmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid A.","family":"Binswanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Morse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Timko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex H. S.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Smelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea K.","family":"Finlay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"issue":"1","key":"93_CR1","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.amepre.2021.06.014","volume":"62","author":"AK Finlay","year":"2022","unstructured":"Finlay AK, Palframan KM, Stimmel M, McCarthy JF. Legal system involvement and opioid-related overdose mortality in U. S. Department of Veterans Affairs patients. Am J Prev Med. 2022;62(1):e29-37.","journal-title":"Am J Prev Med."},{"issue":"23","key":"93_CR2","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1056\/NEJMra1807054","volume":"380","author":"KM Babu","year":"2019","unstructured":"Babu KM, Brent J, Juurlink DN. Prevention of opioid overdose. N Engl J Med. 2019;380(23):2246\u201355.","journal-title":"N Engl J Med"},{"issue":"3","key":"93_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Intern Med. 2018;169(3):137\u201345.","journal-title":"Ann Intern Med"},{"issue":"9","key":"93_CR4","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s11606-020-05944-6","volume":"35","author":"AK Finlay","year":"2020","unstructured":"Finlay AK, Morse E, Stimmel M, Taylor E, Timko C, Harris AHS, et al. Barriers to medications for opioid use disorder among veterans involved in the legal system: a qualitative study. J Gen Intern Med. 2020;35(9):2529\u201336.","journal-title":"J Gen Intern Med"},{"key":"93_CR5","doi-asserted-by":"publisher","first-page":"102768","DOI":"10.1016\/j.drugpo.2020.102768","volume":"81","author":"CE Grella","year":"2020","unstructured":"Grella CE, Ostile E, Scott CK, Dennis M, Carnavale J. A Scoping review of barriers and facilitators to implementation of medications for treatment of opioid use disorder within the criminal justice system. Int J Drug Policy. 2020;81:102768.","journal-title":"Int J Drug Policy"},{"key":"93_CR6","doi-asserted-by":"publisher","first-page":"102978","DOI":"10.1016\/j.drugpo.2020.102978","volume":"87","author":"R Komalasari","year":"2021","unstructured":"Komalasari R, Wilson S, Haw S. A systematic review of qualitative evidence on barriers to and facilitators of the implementation of opioid agonist treatment (OAT) programmes in prisons. Int J Drug Policy. 2021;87:102978.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"93_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1370\/afm.1735","volume":"13","author":"RA Rosenblatt","year":"2015","unstructured":"Rosenblatt RA, Andrilla CHA, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23\u20136.","journal-title":"Ann Fam Med"},{"issue":"3","key":"93_CR8","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.idc.2020.06.012","volume":"34","author":"D Winetsky","year":"2020","unstructured":"Winetsky D, Fox A, Nijhawan A, Rich JD. Treating opioid use disorder and related infectious diseases in the criminal justice system. Infect Dis Clin North Am. 2020;34(3):585\u2013603.","journal-title":"Infect Dis Clin North Am"},{"key":"93_CR9","unstructured":"U.S. Department of Veterans Affairs enrollment provisions and medical benefits package( (\u00a7 17.3838 C.F.R. \u00a7 17.38(c)(5)). Washington, D.C.: U.S. Department of Veterans Affairs."},{"key":"93_CR10","unstructured":"Social Security Act (42 U.S.C. \u00a7 1315 Medicaid Reentry Section 1115 Demonstration Opportunity). Washington, D.C.: Department of Health and Human Services."},{"issue":"10324","key":"93_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(21)02252-2","volume":"399","author":"K Humphreys","year":"2022","unstructured":"Humphreys K, Shover CL, Andrews CM, Bohnert ASB, Brandeau ML, Caulkins JP, et al. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission. Lancet. 2022;399(10324):555\u2013604.","journal-title":"Lancet"},{"issue":"1","key":"93_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1037\/a0029652","volume":"10","author":"JH Blue-Howells","year":"2013","unstructured":"Blue-Howells JH, Clark SC, van den Berk-Clark C, McGuire JF. The U. S. Department of Veterans Affairs Veterans Justice Programs and the sequential intercept model: case examples in national dissemination of intervention for justice-involved veterans. Psychol Serv. 2013;10(1):48\u201353.","journal-title":"Psychol Serv."},{"issue":"2","key":"93_CR13","first-page":"357","volume":"35","author":"RT Russell","year":"2009","unstructured":"Russell RT. Veterans treatment court: a proactive approach. N Engl J Crim Civ Confin. 2009;35(2):357\u201372.","journal-title":"N Engl J Crim Civ Confin"},{"key":"93_CR14","unstructured":"VHA Directive Veterans Justice Programs (1162.06.). Washington, D.C., U.S. Department of Veterans Affairs."},{"key":"93_CR15","unstructured":"Uniform Mental Health Services in VA medical centers and clinics (VHA Handbook 1160.1). Washington, D.C., U.S. Department of Veterans Affairs."},{"key":"93_CR16","doi-asserted-by":"crossref","unstructured":"Finlay AK, Harris AHS, Timko C, Yu M, Smelson D, Stimmel M, et al. Disparities in access to medications for opioid use disorder in the Veterans Health Administration. J Addict Med. 2020;15(2):143\u201349.","DOI":"10.1097\/ADM.0000000000000719"},{"issue":"9","key":"93_CR17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","volume":"89","author":"BC O\u2019Brien","year":"2014","unstructured":"O\u2019Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med J Assoc Am Med Coll. 2014;89(9):1245\u201351.","journal-title":"Acad Med J Assoc Am Med Coll"},{"issue":"141","key":"93_CR18","doi-asserted-by":"publisher","first-page":"108850","DOI":"10.1016\/j.jsat.2022.108850","volume":"1","author":"DB Marlowe","year":"2022","unstructured":"Marlowe DB, Theiss DS, Ostlie EM, Carnevale J. Drug court utilization of medications for opioid use disorder in high opioid mortality communities. J Subst Abuse Treat. 2022;1(141):108850.","journal-title":"J Subst Abuse Treat"},{"key":"93_CR19","unstructured":"Atlas.ti. Version 8. Berlin (GER): Atlas.ti Scientific Software Development GmbH. 2019. Available from: https:\/\/atlasti.com\/."},{"issue":"1","key":"93_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How many interviews are enough?: An experiment with data saturation and variability. Field Methods. 2006;18(1):59\u201382.","journal-title":"Field Methods"},{"issue":"4","key":"93_CR21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1177\/1049732316665344","volume":"27","author":"MM Hennink","year":"2017","unstructured":"Hennink MM, Kaiser BN, Marconi VC. Code saturation versus meaning saturation: how many interviews are enough? Qual Health Res. 2017;27(4):591\u2013608.","journal-title":"Qual Health Res"},{"issue":"6","key":"93_CR22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1177\/104973230201200611","volume":"12","author":"JB Averill","year":"2002","unstructured":"Averill JB. Matrix analysis as a complementary analytic strategy in qualitative inquiry. Qual Health Res. 2002;12(6):855\u201366.","journal-title":"Qual Health Res"},{"key":"93_CR23","unstructured":"Adult drug court best practice standards. Alexandria (VA): National Association of Drug Court Professionals (US); 2024. Available from: https:\/\/allrise.org\/wp-content\/uploads\/2024\/05\/Adult-Treatment-Court-Best-Practice-Standards-I-VI_VIII_X-final.pdf."},{"key":"93_CR24","unstructured":"Johns Hopkins Bloomberg School of Public Health, NYU Grossman School of Medicine, NaphCare, Yale University and National Harm Reduction Coalition, Rhode Island Department of Corrections, Viaduct Consulting LLC, et al. Medications for opioid use disorder in jails and prisons: moving toward universal access. Baltimore (MD): Johns Hopkins Bloomberg School of Public Health (US); 2021. Available from: https:\/\/americanhealth.jhu.edu\/sites\/default\/files\/2021-08\/JHU-014%20OUD%20in%20Jail%20Report%20FINAL%202.pdf."},{"key":"93_CR25","unstructured":"National Academy for State Health Policy. States allowing telehealth prescriptions for opioid use disorder [Internet]. NASHP. 2021 [cited 2024 Jun 28]. Available from: https:\/\/nashp.org\/state-tracker\/states-allowing-telehealth-prescriptions-for-opioid-use-disorder\/"},{"key":"93_CR26","unstructured":"Mette E. Litigation prompting state and local correctional systems to change opioid use disorder treatment policies [Internet]. NASHP. 2021 [cited 2024 Jun 28]. Available from: https:\/\/nashp.org\/litigation-prompting-state-and-local-correctional-systems-to-change-opioid-use-disorder-treatment-policies\/"},{"issue":"2","key":"93_CR27","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1097\/ADM.0000000000001079","volume":"17","author":"MN Poulsen","year":"2023","unstructured":"Poulsen MN, Santoro W, Scotti R, Henderson C, Ruddy M, Colistra A. Implementation of telemedicine delivery of medications for opioid use disorder in Pennsylvania treatment programs during COVID-19. J Addict Med. 2023;17(2):e110\u20138.","journal-title":"J Addict Med"},{"issue":"2","key":"93_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/10826084.2022.2155480","volume":"58","author":"C Harrington","year":"2023","unstructured":"Harrington C, Bailey A, Delorme E, Hano S, Evans E. \u201cAnd then COVID hits\u201d: a qualitative study of how jails adapted services to treat opioid use disorder during COVID-19. Subst Use Misuse. 2023;58(2):266\u201374.","journal-title":"Subst Use Misuse"},{"issue":"1","key":"93_CR29","doi-asserted-by":"publisher","first-page":"e2144369","DOI":"10.1001\/jamanetworkopen.2021.44369","volume":"5","author":"C Sufrin","year":"2022","unstructured":"Sufrin C, Kramer CT, Terplan M, Fiscella K, Olson S, Voegtline K, et al. Availability of medications for the treatment of opioid use disorder among pregnant and postpartum individuals in US jails. JAMA Netw Open. 2022;5(1):e2144369.","journal-title":"JAMA Netw Open"},{"issue":"149","key":"93_CR30","doi-asserted-by":"publisher","first-page":"209051","DOI":"10.1016\/j.josat.2023.209051","volume":"1","author":"MD Booty","year":"2023","unstructured":"Booty MD, Harp K, Batty E, Knudsen HK, Staton M, Oser CB. Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: perspectives from clinicians. J Subst Use Addict Treat. 2023;1(149):209051.","journal-title":"J Subst Use Addict Treat"},{"key":"93_CR31","volume-title":"Standards of care: for the addiction specialist physician","author":"American Society of Addiction Medicine","year":"2014","unstructured":"American Society of Addiction Medicine. Standards of care: for the addiction specialist physician. Chevy Chase: American Society of Addiction Medicine; 2014."},{"issue":"8","key":"93_CR32","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1177\/0887403415620633","volume":"28","author":"AS Douds","year":"2017","unstructured":"Douds AS, Ahlin EM, Howard D, Stigerwalt S. Varieties of veterans\u2019 courts: a statewide assessment of veterans\u2019 treatment court components. Crim Justice Policy Rev. 2017;28(8):740\u201369.","journal-title":"Crim Justice Policy Rev"},{"issue":"1","key":"93_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40352-022-00188-4","volume":"10","author":"FZ Ahmed","year":"2022","unstructured":"Ahmed FZ, Andraka-Christou B, Clark MH, Totaram R, Atkins DN, del Pozo B. Barriers to medications for opioid use disorder in the court system: provider availability, provider \u201ctrustworthiness\u201d, and cost. Health Justice. 2022;10(1):24.","journal-title":"Health Justice"},{"issue":"234","key":"93_CR34","doi-asserted-by":"publisher","first-page":"109394","DOI":"10.1016\/j.drugalcdep.2022.109394","volume":"1","author":"E Pivovarova","year":"2022","unstructured":"Pivovarova E, Evans EA, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Legislatively mandated implementation of medications for opioid use disorders in jails: a qualitative study of clinical, correctional, and jail administrator perspectives. Drug Alcohol Depend. 2022;1(234):109394.","journal-title":"Drug Alcohol Depend"},{"issue":"0","key":"93_CR35","first-page":"1","volume":"0","author":"M Staton","year":"2023","unstructured":"Staton M, Pike E, Levi M, Lofwall M. The importance of justice and health care partnerships in MOUD feasibility trials. J Soc Work Pract Addict. 2023;0(0):1\u201315.","journal-title":"J Soc Work Pract Addict."},{"issue":"1","key":"93_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00288-9","volume":"7","author":"LB Puglisi","year":"2021","unstructured":"Puglisi LB, Wang EA. Health care for people who are incarcerated. Nat Rev Dis Primer. 2021;7(1):1\u20132.","journal-title":"Nat Rev Dis Primer"},{"issue":"4","key":"93_CR37","doi-asserted-by":"publisher","first-page":"472","DOI":"10.2105\/AJPH.2017.304248","volume":"108","author":"J Pont","year":"2018","unstructured":"Pont J, Enggist S, St\u00f6ver H, Williams B, Greifinger R, Wolff H. Prison health care governance: guaranteeing clinical independence. Am J Public Health. 2018;108(4):472\u20136.","journal-title":"Am J Public Health"},{"issue":"1","key":"93_CR38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1080\/08897077.2021.1975867","volume":"43","author":"EN Taylor","year":"2022","unstructured":"Taylor EN, Timko C, Binswanger IA, Harris AHS, Stimmel M, Smelson D, et al. A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration. Subst Abuse. 2022;43(1):556\u201363.","journal-title":"Subst Abuse"},{"issue":"1","key":"93_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40352-021-00143-9","volume":"9","author":"CK Scott","year":"2021","unstructured":"Scott CK, Dennis ML, Grella CE, Mischel AF, Carnevale J. The impact of the opioid crisis on U. S. state prison systems. Health Justice. 2021;9(1):17.","journal-title":"Health Justice."},{"issue":"2","key":"93_CR40","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/08897077.2019.1695706","volume":"41","author":"ER Brezel","year":"2020","unstructured":"Brezel ER, Powell T, Fox AD. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated. Subst Abuse. 2020;41(2):150\u20134.","journal-title":"Subst Abuse"},{"key":"93_CR41","unstructured":"National Sheriffs\u2019 Association. Jail-based medication-assisted treatment: promising practices, guidelines, and resources for the field. Alexandria (VA); National Sheriffs' Association (US); 2018. Available from: https:\/\/www.sheriffs.org\/publications\/Jail-Based-MAT-PPG.pdf."},{"key":"93_CR42","unstructured":"Substance Abuse and Mental Health Services Administration. Use of medication-assisted treatment for opioid use disorder in criminal justice settings. Rockville (MD); Substance Abuse and mental Health Services Administration (US); 2019. Available from: https:\/\/store.samhsa.gov\/product\/Use-of-Medication-Assisted-Treatment-for-Opioid-Use-Disorder-in-Criminal-Justice-Settings\/PEP19-MATUSECJS."},{"key":"93_CR43","unstructured":"Weizman S, Perez J, Manoff I, Baney M, El-Sabawi T. A national snapshot: Access to medications for opioid use disorder in U.S. jails and prisons - litigation, legislation, and policies. Washington, D.C.; O\u2019Neill Institute for National and Global Health Law (US); 2021. Available from: https:\/\/oneill.law.georgetown.edu\/publications\/national-snapshot-access-to-medications-for-opioid-use-disorder-in-u-s-jails-and-prisons\/."},{"key":"93_CR44","unstructured":"Estelle v. Gamble (1976) 429 US 97."},{"key":"93_CR45","unstructured":"Council on Criminal Justice. Medicaid and reentry: policy changes and considerations for improving public health and public safety. Washington, D.C.; Council on Criminal Justice (US); 2022. Available from: https:\/\/counciloncj.org\/health-and-reentry-project-brief-issue-1\/."},{"key":"93_CR46","unstructured":"Bureau of Justice Assistance. Managing substance withdrawal in jails: a legal brief. Washington, D.C.; Department of Justice (US); 2022. Report No.: NCJ 304066."}],"container-title":["BMC Global and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44263-024-00093-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44263-024-00093-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44263-024-00093-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T09:51:21Z","timestamp":1732787481000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcglobalpublichealth.biomedcentral.com\/articles\/10.1186\/s44263-024-00093-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["93"],"URL":"https:\/\/doi.org\/10.1186\/s44263-024-00093-y","relation":{},"ISSN":["2731-913X"],"issn-type":[{"value":"2731-913X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"11 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Stanford University\u2019s Institutional Review Board (eprotocol #40213) and the VA Palo Alto Research & Development committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IB is a Guest Editor for the article collection; however, peer review of any submissions for which the Guest Editors have competing interests is handled by another Editor or Editorial Board Member who has no competing interests. The authors have no other conflicts of interest or disclosures to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}